415 related articles for article (PubMed ID: 31961053)
21. Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden.
Makimoto G; Ohashi K; Tomida S; Nishii K; Matsubara T; Kayatani H; Higo H; Ninomiya K; Sato A; Watanabe H; Kano H; Ninomiya T; Kubo T; Rai K; Ichihara E; Hotta K; Tabata M; Toyooka S; Takata M; Maeda Y; Kiura K
J Thorac Oncol; 2019 Nov; 14(11):2009-2018. PubMed ID: 31374369
[TBL] [Abstract][Full Text] [Related]
22. Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report.
Wiedemann C; Kazdal D; Cvetkovic J; Kunz J; Fisch D; Kirchner M; Kriegsmann M; Sültmann H; Heussel CP; Bischoff H; Thomas M; Stenzinger A; Christopoulos P
Cold Spring Harb Mol Case Stud; 2022 Oct; 8(6):. PubMed ID: 36207130
[TBL] [Abstract][Full Text] [Related]
23. Treatment of advanced ALK-rearranged NSCLC following second-generation ALK-TKI failure.
Fukuda A; Yoshida T
Expert Rev Anticancer Ther; 2023; 23(11):1157-1167. PubMed ID: 37772744
[TBL] [Abstract][Full Text] [Related]
24. The efficacy and safety of ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer: A network meta-analysis.
Fan J; Fong T; Xia Z; Zhang J; Luo P
Cancer Med; 2018 Oct; 7(10):4993-5005. PubMed ID: 30230699
[TBL] [Abstract][Full Text] [Related]
25. Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer.
Yu Y; Ou Q; Wu X; Bao H; Ding Y; Shao YW; Lu S
Lung Cancer; 2019 Jan; 127():19-24. PubMed ID: 30642546
[TBL] [Abstract][Full Text] [Related]
26. Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC.
Zhu Q; Hu H; Weng DS; Zhang XF; Chen CL; Zhou ZQ; Tang Y; Xia JC
BMC Cancer; 2017 Jun; 17(1):412. PubMed ID: 28606126
[TBL] [Abstract][Full Text] [Related]
27. Background and rationale of the eXalt3 trial investigating X-396 in the treatment of ALK+ non-small-cell lung cancer.
Singhi EK; Horn L
Future Oncol; 2018 Aug; 14(18):1781-1787. PubMed ID: 29506392
[TBL] [Abstract][Full Text] [Related]
28. Dissecting the role of ALK double mutations in drug resistance to lorlatinib with in-depth theoretical modeling and analysis.
Zhang X; Tong J; Wang T; Wang T; Xu L; Wang Z; Hou T; Pan P
Comput Biol Med; 2024 Feb; 169():107815. PubMed ID: 38128254
[TBL] [Abstract][Full Text] [Related]
29. A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib.
Sharma GG; Cortinovis D; Agustoni F; Arosio G; Villa M; Cordani N; Bidoli P; Bisson WH; Pagni F; Piazza R; Gambacorti-Passerini C; Mologni L
J Thorac Oncol; 2019 Nov; 14(11):e257-e259. PubMed ID: 31668326
[No Abstract] [Full Text] [Related]
30. Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC.
Ma X; Zhang K; Xu J; Gao H; Yang S; Qin H; Wang H; Gao F; Liu X
Thorac Cancer; 2023 Jul; 14(20):1980-1990. PubMed ID: 37265111
[TBL] [Abstract][Full Text] [Related]
31. Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients.
Hua G; Zhang X; Zhang M; Wang Q; Chen X; Yu R; Bao H; Liu J; Wu X; Shao Y; Liang B; Lu K
ESMO Open; 2022 Feb; 7(1):100337. PubMed ID: 35123209
[TBL] [Abstract][Full Text] [Related]
32. ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression.
Ou SH; Milliken JC; Azada MC; Miller VA; Ali SM; Klempner SJ
Lung Cancer; 2016 Jan; 91():70-2. PubMed ID: 26464158
[TBL] [Abstract][Full Text] [Related]
33. Response to lorlatinib on a patient with ALK-rearranged non-small cell lung cancer harboring 1151Tins mutation with uterine metastasis.
Kobayashi T; Kanda S; Fukushima T; Noguchi T; Sekiguchi N; Koizumi T
Thorac Cancer; 2021 Aug; 12(16):2275-2278. PubMed ID: 34184417
[TBL] [Abstract][Full Text] [Related]
34. Second-generation ALK inhibitors: filling the non "MET" gap.
Ramalingam SS; Khuri FR
Cancer Discov; 2014 Jun; 4(6):634-6. PubMed ID: 24891360
[TBL] [Abstract][Full Text] [Related]
35. Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.
Naito T; Shiraishi H; Fujiwara Y
Jpn J Clin Oncol; 2021 Jan; 51(1):37-44. PubMed ID: 33147606
[TBL] [Abstract][Full Text] [Related]
36. First-Line Lorlatinib or Crizotinib in Advanced
Shaw AT; Bauer TM; de Marinis F; Felip E; Goto Y; Liu G; Mazieres J; Kim DW; Mok T; Polli A; Thurm H; Calella AM; Peltz G; Solomon BJ;
N Engl J Med; 2020 Nov; 383(21):2018-2029. PubMed ID: 33207094
[TBL] [Abstract][Full Text] [Related]
37. Ceritinib Treatment for Carcinomatous Meningitis with a Secondary Mutation at I1171T in Anaplastic Lymphoma Kinase.
Ashinuma H; Shingyoji M; Hasegawa Y; Yokoi S; Yoshida Y
Intern Med; 2018 Nov; 57(21):3153-3155. PubMed ID: 29877262
[TBL] [Abstract][Full Text] [Related]
38. Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.
Lin JJ; Zhu VW; Yoda S; Yeap BY; Schrock AB; Dagogo-Jack I; Jessop NA; Jiang GY; Le LP; Gowen K; Stephens PJ; Ross JS; Ali SM; Miller VA; Johnson ML; Lovly CM; Hata AN; Gainor JF; Iafrate AJ; Shaw AT; Ou SI
J Clin Oncol; 2018 Apr; 36(12):1199-1206. PubMed ID: 29373100
[TBL] [Abstract][Full Text] [Related]
39. [Second generation ALK inhibitors in non-small cell lung cancer: systemic review].
Viala M; Brosseau S; Planchard D; Besse B; Soria JC
Bull Cancer; 2015 Apr; 102(4):381-9. PubMed ID: 25819217
[TBL] [Abstract][Full Text] [Related]
40. Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?
Ou SI; Lee TK; Young L; Fernandez-Rocha MY; Pavlick D; Schrock AB; Zhu VW; Milliken J; Ali SM; Gitlitz BJ
Lung Cancer; 2017 Apr; 106():110-114. PubMed ID: 28285684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
